Microbix Biosystems reports Q2 EPS (C$0.01) vs. C$0.00 last year

Reports Q2 revenue C$3.38M vs. C$5.32M last year. The company said, “Results for Q2 and H1 demonstrated early results of the Company’s continuing work to rebuild revenues back to profitability following two client setbacks in mid-2025, with revenue growth of 5% in H1 compared to H2 fiscal 2025. Microbix is prepared for material sales growth following additions to its capabilities and capacity. It is now at work on adding new client programs and clients to counter setbacks with two large clients in 2025. Progress with business development will be announced when secured. Microbix anticipates full-year fiscal 2026 results in-line with the forward-looking information (FLI) disclosed in its current Management Discussion and Analysis, towards rebuilding sales above its earnings breakeven point.”